Latest KFF Health News Stories
Older Americans Quit Weight Loss Drugs in Droves
In some studies, half of patients stopped taking GLP-1s within a year despite the benefits, citing the expense and side effects.
In Mississippi, Medicaid Coverage of Weight Loss Drugs Fails To Catch On
In Mississippi, a state with one of the highest obesity rates in the nation, Medicaid covers weight loss drugs, but few enrollees have signed up for the benefit.
As Insurers Struggle With GLP-1 Drug Costs, Some Seek To Wean Patients Off
Conventional wisdom says GLP-1 drugs must be taken indefinitely to maintain weight loss. But a growing number of researchers, payers, and providers are challenging that consensus and exploring whether — and how — to taper patients off expensive GLP-1 drugs.
Chronically Ill? In Kennedy’s View, It Might Be Your Own Fault
In their zeal to “Make America Healthy Again,” top Trump administration officials depict patients and the doctors who treat them as partly responsible for whatever ails them.
A Revolutionary Drug for Extreme Hunger Offers Clues to Obesity’s Complexity
A new drug is helping families who’ve spent years padlocking fridges, chaining garbage cans, and hiding food as their children with Prader-Willi syndrome deal with unrelenting hunger. But additional progress — and a broader understanding of obesity — is now under threat as the government dismantles the pipeline for promising new research.
Trump Won’t Force Medicaid To Cover GLP-1s for Obesity. A Few States Are Doing It Anyway.
Late last year, South Carolina Medicaid approved a class of medications known as GLP-1s to treat obesity, placing it among the few state programs covering these effective but expensive drugs. But access remains limited, even for patients covered by Medicaid, because of stringent prerequisites that must be satisfied before starting the drug.
Junk Food Turns Public Villain as Power Shifts in Washington
Some Trump insiders are ready to take on the food industry. It remains to be seen whether their entrée will result in any meaningful change in government oversight of “Big Food” — or in American health.
La comida chatarra es la nueva villana de Washington
Los candidatos a las principales agencias de salud están apuntando a los alimentos ultraprocesados, que representan aproximadamente el 70% del suministro de alimentos de Estados Unidos.
Journalists Dig Into Vaccine Debate and America’s Obesity Rates
KFF Health News staff made the rounds on national and local media in recent weeks to discuss topical stories. Here’s a collection of their appearances.
Journalists Talk Obesity, Oximeters, and Severe Weather’s Impact on Public Health
KFF Health News and California Healthline staff made the rounds on national and local media in recent weeks to discuss topical stories. Here’s a collection of their appearances.
How Little Denmark Got Homegrown Giant Novo Nordisk To Lower Ozempic Prices
As Congress pushes for Medicare to cover payment for anti-obesity drugs, Denmark — Ozempic maker Novo Nordisk’s home — has limited coverage of the drug after cost overruns “emptied all the money boxes in the entire public health system.”
Copycat Weight-Loss Drugs Are Major Players With Consumers
As many as 1 in 8 American adults has tried one of the GLP-1 anti-obesity drugs, but a surprising number aren’t getting their supplies from pharma giants Novo Nordisk or Eli Lilly. Up to 30 percent of the market, by some estimates, is made up of copycat versions from compounding pharmacies. Compounding is legal, though […]
Why Millions Are Trying FDA-Authorized Alternatives to Big Pharma’s Weight Loss Drugs
Although Novo Nordisk and Lilly lump together the pharmacies that compound semaglutide and tirzepatide with internet cowboys selling fake drugs, there is a distinction. The FDA has offered Americans little clarity about the vast gray and black markets for the drugs.
Qué son los medicamentos compuestos que millones de personas usan para bajar de peso
La FDA permite e incluso fomenta que las farmacias de compuestos produzcan y vendan copias cuando un medicamento está en escasez, como es el caso de las drogas para combatir el sobrepeso y la obesidad.
Weight-Loss Drugs Are So Popular They’re Headed for Medicare Negotiations
The steep prices — and popularity — of Ozempic and similar weight-loss and diabetes drugs could soon make them a priority for Medicare drug price negotiations. List prices for a month’s supply of the drugs range from $936 to $1,349, according to the Peterson-KFF Health System Tracker. The Inflation Reduction Act President Biden signed in […]
Journalists Talk Cost of Weight Loss Drugs and Lack of Obesity Doctors to Manage Their Use
KFF Health News and California Healthline staff made the rounds on national and local media this week to discuss topical stories. Here’s a collection of their appearances.
High Price of Popular Diabetes Drugs Deprives Low-Income People of Effective Treatment
The makers of Ozempic and Mounjaro charge list prices of around $1,000 a month for the diabetes and obesity drugs, and insurers are reluctant to pick up the tab. Often, low-income patients have to resort to less effective treatments.
Personas de bajos ingresos no pueden recibir terapias efectivas contra la diabetes por el alto costo
La escasez de suministros y las barreras que ponen las aseguradoras para obtener esta poderosa clase de medicamentos, llamados agonistas de GLP-1, han dejado a muchas personas que viven con diabetes y obesidad sin los medicamentos que necesitan para mantenerse saludables.
Arkansas Led the Nation in Measuring Obesity in Kids. Did It Help?
For more than 20 years, children in Arkansas have been measured in school as part of a statewide effort to reduce childhood obesity. But the letters have had no impact on weight loss — and obesity rates have risen. Still, the practice of sending letters has spread to other states.
What the Health? From KFF Health News: On Abortion Rights, Ohio Is the New Kansas
Nearly a year to the day after Kansas voters surprised the nation by defeating an anti-abortion ballot question, Ohio voters defeated a similar, if cagier, effort to limit access in that state. This week, they rejected an effort to raise the threshold for approval of future ballot measures from a simple majority, which would have made it harder to protect abortion access with yet another ballot question come November. Meanwhile, the number of Americans without health insurance has dropped to an all-time low, though few noticed. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Rachel Roubein of The Washington Post, and Emmarie Huetteman of KFF Health News join KFF Health News’ chief Washington correspondent, Julie Rovner, to discuss these issues and more. Also this week, Rovner interviews Kate McEvoy, executive director of the National Association of Medicaid Directors, about how the “Medicaid unwinding” is going, as millions have their eligibility for coverage rechecked.
